Lenvatinib for HCC: CHA Bundang Medical Center Study

by Archynetys Health Desk December 1, 2025

December 1, 2025

The research team of Professors Jeon Hong-jae and Kim Jeong-seon of the Department of Oncology at Bundang CHA Medical Center used a combination of Atezolizumab and Bevacizumab. therapyHepatocellular carcinoma (HCC) patients who failed (A+B)…

Archynetys Health Desk

The Archynetys Health Desk covers public health, medical research, healthcare systems, wellness trends, and science-backed developments that affect readers globally. This desk applies added care to sourcing, evidence, nuance, and plain-language explanation, especially on high-impact health topics.

Lenvatinib for HCC: CHA Bundang Medical Center Study

Share this:

Related

Strategy Buys 130 More Bitcoin – Now Over 650K Holdings

Böhse Onkelz Leipzig: Fake Tickets & Concert Scam

Related Posts

Leave a Comment Cancel Reply